Cengild Medical Berhad (KLSE:CENGILD)

Market Cap	208.23M
Revenue (ttm)	77.14M
Net Income (ttm)	10.37M
Shares Out	832.91M
EPS (ttm)	0.01
PE Ratio	20.16
Forward PE	n/a
Dividend	0.01 (4.90%)
Ex-Dividend Date	Feb 12, 2025

Volume	152,500
Average Volume	922,610
Open	0.2450
Previous Close	0.2500
Day's Range	0.2400 - 0.2450
52-Week Range	0.2200 - 0.3050
Beta	-0.06
RSI	59.14
Earnings Date	Aug 22, 2025

About Verve Therapeutics

Cengild Medical Berhad, an investment holding company, operates a medical center in Malaysia. The company offers various care and treatment consultant services for gastrointestinal and liver diseases, morbid obesity, and oncology and urological conditions; general cardiology and gynecology assessment; gastroenterology and hepatology; anesthesiology, endocrinology, general surgery, internal medicine, orthopedic, plastic and reconstructive surgery, radiology, rheumatology, and thoracic surgery; ear, nose and throat; gastrointestinal surgeries, in...

• Industry: Health Services
• Founded: 2017
• Employees: 159
• Stock Exchange: Bursa Malaysia
• Ticker Symbol: CENGILD

Financial Performance

In 2024, Cengild Medical Berhad's revenue was 66.85 million, a decrease of -4.88% compared to the previous year's 70.28 million. Earnings were 11.08 million, a decrease of -16.64%.